Trends in adherence to secondary prevention medications in elderly post‐myocardial infarction patients

Poor levels of medication adherence for patients with coronary heart disease (CHD) have been documented but it is unclear whether adherence has improved over time.

[1]  William H Shrank,et al.  Cost-Effectiveness of Providing Full Drug Coverage to Increase Medication Adherence in Post–Myocardial Infarction Medicare Beneficiaries , 2008, Circulation.

[2]  E. Bates.  2007 focused update of the ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. , 2008, Polskie Archiwum Medycyny Wewnetrznej.

[3]  Christopher E. Buller,et al.  2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2008, Circulation.

[4]  W. Winkelmayer,et al.  Medication Adherence After Myocardial Infarction: A Long Way Left To Go , 2008, Journal of general internal medicine.

[5]  W. J. Elliott,et al.  Interventions to Enhance Medication Adherence in Chronic Medical Conditions: A Systematic Review , 2008 .

[6]  Thomas H. Lee.  Eulogy for a quality measure. , 2007, The New England journal of medicine.

[7]  K. Eagle,et al.  The association between guideline-based treatment instructions at the point of discharge and lower 1-year mortality in Medicare patients after acute myocardial infarction: the American College of Cardiology's Guidelines Applied in Practice (GAP) initiative in Michigan. , 2007, American heart journal.

[8]  D. Alter,et al.  Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. , 2007, JAMA.

[9]  E. Antman,et al.  Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis. , 2007, Health affairs.

[10]  Harlan M Krumholz,et al.  Impact of medication therapy discontinuation on mortality after myocardial infarction. , 2006, Archives of internal medicine.

[11]  K. Anstrom,et al.  National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. , 2006, American heart journal.

[12]  P. Wolf,et al.  Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2006, Circulation.

[13]  D. Lawlor,et al.  Secondary prevention of coronary heart disease in older patients after the national service framework: population based study , 2006, BMJ : British Medical Journal.

[14]  P. Box.  Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease , 2006 .

[15]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[16]  L. Osterberg,et al.  Adherence to medication. , 2005, The New England journal of medicine.

[17]  R. Verbrugge,et al.  Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost , 2005, Medical care.

[18]  Lippincott Williams Wilkins,et al.  ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction , 2004 .

[19]  Karl Swedberg,et al.  Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. , 2004, European heart journal.

[20]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[21]  K. Swedberg,et al.  Expert consensus document on beta-adrenergic receptor blockers. , 2004, European heart journal.

[22]  H. Mcdonald,et al.  Interventions to enhance patient adherence to medication prescriptions: scientific review. , 2002, JAMA.

[23]  Muhammad Mamdani,et al.  Adherence with statin therapy in elderly patients with and without acute coronary syndromes. , 2002, JAMA.

[24]  P. Thompson,et al.  Magnetic resonance imaging of left atrial thrombus , 2002, Heart.

[25]  M. Weinstein,et al.  Long-term persistence in use of statin therapy in elderly patients. , 2002, JAMA.

[26]  A. Connor,et al.  The way I see it: House officers need formal career development , 2002 .

[27]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[28]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[29]  S. Yusuf,et al.  Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. , 2001, Circulation.

[30]  E. Antman,et al.  The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. , 2000, JAMA.

[31]  K. Labresh,et al.  Get with the guidelines. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[32]  D. Redelmeier,et al.  The treatment of unrelated disorders in patients with chronic medical diseases. , 1998, The New England journal of medicine.

[33]  J. Avorn,et al.  Persistence of use of lipid-lowering medications: a cross-national study. , 1998, JAMA.

[34]  A V Prochazka,et al.  The assessment of refill compliance using pharmacy records: methods, validity, and applications. , 1997, Journal of clinical epidemiology.

[35]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[36]  T C Chalmers,et al.  Cumulative meta-analysis of therapeutic trials for myocardial infarction. , 1992, The New England journal of medicine.